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Highlights:  
 
1) Plasma combined free light chains (cFLC) are increased in patients with acute heart 
failure 
2) In patients with acute heart failure cFLC remain elevated during 3 months after 
admission 
3) cFLC are strong independent predictors of poor outcome in patients with acute 
heart failure 
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Abstract 
Increased combined free light chains (cFLC) are strongly prognostic of death in general 
populations and in patients with chronic kidney disease, but scarce data are available on 
cFLC in heart failure (HF). We aimed to assess the dynamics and prognostic significance of 
cFLC levels in patients following admission with acute heart failure (AHF). cFLC 
measurements were compared in 49 patients with AHF, 37 patients with stable HF, 43 
patients with stable coronary artery disease and without HF (‘disease controls’), and 37 
healthy controls. The association of cFLC with death and/or rehospitalisation was assessed. 
Patients with AHF had significantly elevated cFLC levels, compared to other groups 
(p<0.001). Patients with stable HF showed higher levels of cFLC than healthy controls. In 
AHF, cFLC levels correlated with cystatin C (Spearman r=0.63, p<0.001), and creatinine 
(Spearman r=0.47, p=0.002). During 3 months follow up brain natriuretic peptide (BNP) 
reduced significantly (p=0.017), but cFLC did not change significantly. In a multivariate Cox 
regression analysis, the higher quartiles of cFLC were significantly associated with 
death/readmission (hazard ratio (HR) 8.34 [95% CI 2.38-29.22] p=0.0009) after adjustment 
for age, gender, BNP and cystatin C levels. Higher quartiles of cFLC were prognostic for 
death alone (HR 14.0 [95% CI 1.72-113.8], p=0.014). In conclusion, raised serum cFLC 
concentrations in patients with AHF were independently associated with prognosis. In AHF, 
elevated cFLC levels persist long after clinical stabilisation, which may reflect immune 
disturbances and/or the reduced capacity of (perhaps functionally impaired) kidneys and the 
endothelium to eliminate them. 
Key words: free light chains, heart failure, coronary artery disease 
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Introduction 
 
Heart failure (HF) is a significant contributor to overall mortality in the community and 
high levels of combined free light chains (cFLC) were associated with increased mortality in 
the general population.1,2 Also cFLC levels have been reported to be associated with 
unfavourable outcome in chronic kidney disease where cardiovascular disease was the major 
cause of death; CKD is common finding in patients with HF.3 In the present study, we tested 
the hypothesis that cFLC levels are abnormal in HF, with the greatest abnormalities seen in 
acute decompensated HF. Second, we hypothesised that cFLC levels would have prognostic 
implications for ‘death and HF hospitalisation’ 
 
Methods 
 
Forty nine consecutive patients admitted to hospital with acute HF (AHF group) of 
ischemic etiology were recruited and compared to 37 patients with stable chronic HF (SHF 
group), 43 patients with stable coronary artery disease free from HF (CAD group, ‘disease 
controls’), and 37 healthy controls (HC group). AHF was defined in accordance with the 
European Society of Cardiology guidelines as the rapid onset/progression of HF symptoms 
and signs related to reduced cardiac contractility requiring hospital admission (New York 
Heart Association (NYHA) class symptoms).4 All patients had left ventricular ejection 
fraction (LVEF) of ≤40% on echocardiography or left ventriculography. Patients were 
excluded if the hospital admission was caused by an acute coronary syndrome (chest pain 
with ST/T wave changes on electrocardiogram ± positive troponin) or haemodynamically 
compromising arrhythmia or valvular pathology.  
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The SHF group included patients with LVEF ≤40% and no deterioration in clinical 
condition, hospital admission or change in medication for the preceding six months. All SHF 
patients had an ischaemic etiology of HF. In this group, 10 (27%) patients had NYHA I class 
symptoms, 24 (65%) patients had NYHA II class symptoms, and 3 (8%) had NYHA III class 
symptoms. For CAD ‘disease control’ group eligibility, criteria included history of 
myocardial infarction >6 months previously and/or angiographically documented stenosis 
>50% in ≥1 coronary artery and LVEF >50%. Patients with SHF and CAD were recruited 
from outpatient clinics at Sandwell and West Birmingham Hospitals NHS Trust. The study 
was performed in accordance with the Helsinki declaration and was approved by the 
Warwickshire Research Ethics Committee. All participants provided written informed 
consent. 
 
To minimise potential confounders, CAD was the aetiology of HF in all patients. This 
inclusion criterion enabled both AHF and SHF patients to be compared to the CAD group as 
disease controls with a similar profile of cardiovascular risk factors and co-morbidities (e.g. 
diabetes, hypertension) and medications used. For all study groups, exclusion criteria 
included infectious and inflammatory disorders, cancer, haemodynamically significant 
valvular heart disease, creatinine >200 µmol/l), steroids and hormone replacement therapy. 
 
At baseline all participants had a full medical history and clinical examination 
performed by a cardiologist. Non-fasting peripheral venous blood samples were analyzed by 
flow cytometry within 60 minutes of collection and plasma was stored at –70oC for batch 
analysis of biomarkers, including brain natriuretic peptide (BNP), high sensitivity C-reactive 
protein (hsCRP), cFLC and cystatin C. 
 
In order to assess the dynamics of cFLC in AHF over time, blood samples were 
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analyzed at the following time-points: (i) during the first 24 hours after admission, (ii) on the 
day of hospital discharge and (iii) 3 months following hospital admission. Recruitment began 
on 30 October 2009 and all patients were followed until 30 July 2011 to register any cases of 
death or re-hospitalisation. The primary endpoint was defined as a combination of the first 
occurrence of re-hospitalization or death; the secondary endpoint was any-cause of death 
alone.  
 
Cystatin C and cFLC (Combylite™ assay, The Binding Site Group Ltd, Birmingham, 
UK) were measured on the SPAPLUS® turbidimeter (The Binding Site Group Ltd) following 
the manufacturer’s recommendations. The reference ranges were 0.56-0.99mg/L and 9.3-
43.3mg/L (determined in serum samples),1 respectively. Combylite quantifies the combined 
FLC κ and FLC λ concentration in a single assay.5 There was no evidence of monoclonal 
expansions, which could potentially influence FLC concentrations, in any sample either by 
positive serum protein electrophoresis or abnormal FLC κ/λ ratio (Freelite®, The Binding 
Site Group Ltd).6 hsCRP (Siemens, Germany) concentrations were measured on the BNIITM 
nephelometer (Siemens, Germany). 
 
Plasma levels of interleukin-6 were measured by cytometric bead array technology. The 
BD FACSCalibur flow cytometer was used for data acquisition, with FCAP Array v2.0.2 
software (Burnsville, Minnesota, USA) for data analysis. Commercially available Human 
interleukin-6 Flex (Becton Dickenson, Oxford, UK) was used according to the 
manufacturer’s recommendations. The lower limit of detection of interleukin-6 was 1.0pg/ml. 
BNP was measured using a commercially available enzyme immunoassay set (human BNP-
32, Peninsula Laboratories, LLC, CA, USA) according to manufacturer’s specifications.7,8 
The inter- and intra- assay coefficients of variation for interleukin-6 and BNP assays were 
<5%. 
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Normally distributed data are presented as mean ± standard deviation (SD) and non-
normally distributed data are shown as median (interquartile range, IQR). Cross-sectional 
comparisons between the four study populations were made using a chi-square test (for 
categorical variables), one way analysis of variance (ANOVA) with Tukey post-hoc test (for 
normal data) or Kruskal-Wallis test with Dunn’s post-hoc test (for non-normal data). 
Longitudinal analysis was performed using repeated measures ANOVA with Bonferroni 
adjustment (normal data) or Friedman test with Dunn’s post-hoc test (non-normal data). Only 
AHF patients who completed 3 months follow-up were included in the longitudinal analysis. 
For AHF patients, correlation coefficients were calculated by Pearson and Spearman tests for 
normal and non-normal data, respectively. Cox regression analysis was used to establish 
predictive value of the study for parameters for the study outcome. 
 
Kaplan Meier estimates for the distribution of time from index admission to the primary 
end-point were computed and log-rank analysis was performed to compare event free 
survival for patients with values of cFLC, BNP, hsCRP and estimated glomerular filtration 
rate (eGFR) above and below the median value at admission. Data analysis was carried out 
using SPSS 18.0 (SPSS Inc, Chicago, IL, USA) and a two-sided p-value of <0.05 was 
considered statistically significant. 
 
Results 
 
The 3 patient groups (i.e. AHF, SHF, CAD) were comparable for age, gender, blood 
pressure and body mass index (Table 1). Patients with AHF had higher BNP and creatinine 
levels and lower eGFR vs SHF. As expected, patients with AHF more often received loop 
diuretics and less beta-blockers than participants from all other groups. Patients with AHF 
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had increased counts of monocytes and neutrophils and lower haemoglobin concentrations 
compared to other groups (p<0.001). 
 
Patients with AHF had a highly significant increase in levels of cFLC, cystatin C, 
hsCRP, interleukin-6, monocytes and neutrophils compared to other groups (p<0.001) (Table 
1, Figure 1 for cFLC). Also patients with SHF showed higher levels cFLC and cystatin C 
compared with ‘healthy controls’ (p<0.05 and p=0.008, respectively). There were no 
significant differences in hsCRP, interleukin-6 and leukocyte counts between the patients 
with SHF and control groups free from HF. 
 
In AHF cFLC correlated with cystatin C (Spearman r=0.63, p=0.000001), creatinine 
(Spearman r=0.47, p=0.002) and inversely with eGFR (Spearman r=-0.39, p=0.01). Cystatin 
C correlated with creatinine levels (Pearson r=0.70, p=0.0000004) and inversely with eGFR 
(Pearson r=-0.64, p=0.00001). hsCRP correlated with interleukin-6 levels (Spearman r=0.69, 
p=0.0000001), and neutrophil counts (Spearman r=0.51, p=0.004). There was no significant 
association between concentrations of cFLC, cystatin C, hsCRP and LVEF or BNP values. 
 
Thirty-two AHF patients (65%) completed all 3 blood test time-points. The median 
length of hospital stay was 9 days (IQR 5-13). Nineteen patients (39%) reached the primary 
end point of death or re-hospitalization, with a median duration of follow up of 221 days 
(IQR 140-453). Fourteen patients (29%) reached the secondary end point of death. Twelve 
patients died of HF, 1 died from a ruptured abdominal aortic aneurysm and the cause of death 
in one patient was unknown. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
During the 3 month follow up period, there was a significant reduction in BNP 
concentrations (p=0.017), but no significant change in cFLC or hsCRP levels (Table 2). A 
non-significant trend was observed towards a further increase in cystatin C (p=0.072). 
 
cFLC concentrations were significantly higher in patients reaching the primary 
endpoint of death or re-hospitalization (72 [86-118] mg/L) compared to those who remained 
free of events (58 [39-64] mg/L). In a univariate Cox regression analysis, cFLC 
concentrations were highly significantly associated with the primary end-point and remained 
associated with the outcome after adjustment for age, gender, BNP, cystatin C levels and 
LVEF (Table 3). On univariate Cox regression analysis, cFLC concentrations were 
significantly predictive of the occurrence of the secondary end-point (death alone) and 
remained associated with the outcome after adjustment for age, gender, BNP and cystatin C 
levels and LVEF. Levels of hsCRP, interleukin-6 and leukocyte counts were not significantly 
associated with the primary or secondary outcomes (Table 3). 
 
To further establish the predictive significance of cFLC in AHF, its values were 
analysed as quartiles. On univariate Cox regression analysis, quartiles of cFLC were 
significantly associated with the primary end-point (hazard ratio 2.6 [95% confidence interval 
1.6-4.3], p=0.0002) and remained associated with the outcome after adjustment for age, 
gender, BNP and cystatin C levels (hazard ratio 9.4 [95% confidence interval 2.7-32], 
p=0.0004) and after additional adjustment for LVEF (hazard ratio 12.5 [95% confidence 
interval 2.9-54], p=0.001). On a univariate Cox regression analysis, quartiles of cFLC were 
significantly predictive of the occurrence of the secondary end-point (death alone, (hazard 
ratio 2.3 [95% confidence interval 1.3-4.1], p=0.003) and still remained associated with the 
outcome after adjustment for age, gender, BNP and cystatin C levels (hazard ratio 8.5 [95% 
confidence interval 1.8-40], p=0.007). 
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For a Kaplan-Meier analysis, patients were dichotomized using the median cFLC value 
(62 mg/L). Patients with high cFLC (above median levels) had significantly worse outcomes 
(primary endpoint) compared to those below the median levels (log rank, p=0.00004) (Figure 
2). Patients with high cFLC also had a worse outcome for the secondary endpoint (death 
alone) (log rank, p=0.002) (Figure 2). Kaplan-Meier analyses were performed for BNP, 
hsCRP and eGFR levels and no significant predictive values were found for these parameters 
(Supplementary figure 1). 
 
Discussion 
 
In this study, we show for the first time a highly significant rise in cFLC in patients 
with acute decompensated HF. The cFLC levels remained elevated for at least 3 months after 
HF exacerbation and their high concentrations were strongly associated with poor 
intermediate term outcomes. Elevated cFLC have been associated with increased all-cause 
mortality, with circulatory disease being a predominant cause of death; however this is the 
first report linking cFLC to a specific cardiovascular outcome.1,2 
 
Several mechanisms can be responsible for increased cFLC in HF, which could be 
simplified to their increased production due to stimulation of the adaptive immune system 
(i.e., B-cell activation and proliferation)9-11 and impaired elimination due to dysfunction of 
the kidneys or reticulo-endothelial system.12,13 A combination of all these mechanisms is 
likely to take place in the setting of AHF. Indeed, patients with AHF typically show some 
deterioration of renal function and in our study there was a strong association between cFLC 
levels and parameters of renal impairment, particularly cystatin C levels.14 Abnormal cFLC 
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removal from the circulation could also be due to diminished pinocytic activity of capillary 
endothelial cells, which is consistent with endothelial dysfunction that is evident in HF.15-17 
 
Although high total lymphocyte counts are generally linked to a better prognosis in HF, 
sparse clinical data are available on the functionality of B-cell subsets in this condition and 
their role in immune disarrangement in this disorder. Consequently cFLC may potentially 
represent a useful prognostic biomarker in HF patients independent of parameters of high 
intracardiac pressure (i.e.  BNP) and inflammation related to innate immunity (i.e., hsCRP). 
Indeed, in our study hsCRP correlated with inteleukin-6 concentrations and neutrophil 
counts, but showed no significant correlation with cFLC, in agreement with previous data.18 
Importantly, cFLC preserved its prognostic significance even after accounting for renal status 
indicating the cFLC rise is not solely because of renal dysfunction and has incremental 
prognostic significance in this regard. However, investigation into the exact mechanisms of 
cFLC upregulation in HF was beyond the scope of this pilot study. Also, it remains unclear 
whether the prognostic power of cFLC simply reflects the background abnormalities leading 
to their increase or it could also be attributable to direct detrimental effects of high cFLC 
concentrations. FLC can cause mast cell degranulation, alter neutrophil chemotaxis and 
exhibit direct nephrotoxic effects.19,20 Indeed, symptomatic improvement in acute HF treated 
by levosimendan was partly attributable to a reduction in cFLC concentration.21 
 
This pilot study is relatively small in size and the findings need to be confirmed in 
larger studies, which will also allow comparison to other biomarkers. Our work also provides 
only limited insights into mechanisms responsible to cFLC-related abnormalities in HF and 
does not answer the question of whether high cFLC contribute to HF progression or they are 
secondary to other processes, which also cause HF deterioration. These questions need to be 
tested in specifically designed studies. 
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Figure 1. Combined free light chains in the study groups 
AHF, acute heart failure; CAD, coronary artery disease. cFLC, combined free light chains; 
SHF, stable heart failure. Median and interquartile ranges are indicated by the solid lines. 
 
Figure 2. Survival analysis.  
Kaplan-Meier analysis of predictive value of combined free light chains concentrations in 
acute heart failure for the primary outcome of death or re-hospitalisation (left) and the 
secondary outcome of death alone (right). 
 
Supplementary figure 1. Kaplan-Meier analysis of predictive value of the high sensitivity 
C-reactive protein, brain natriuretic peptide and estimated glomerular filtration rate in acute 
heart failure for the primary outcome (top row) and the secondary outcome (bottom row) 
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Table 1. Characteristics of the study groups 
Variable Acute HF 
(n=49) 
Stable HF 
(n=37) 
CAD 
(n=43) 
Healthy 
(n=37) 
p 
Demographic and clinical characteristics 
Age (years) 71±11 70±10 68±9 67±7 0.23 
Men 34 (69%) 30 (81%) 29 (67%) 23(62%) 0.34 
Systolic blood pressure 
(mmHg) 
139±28 124±24 135±18 143±16 0.07 
Body mass index 
(kg/m2) 
28±5 29±4 28±4 26±3 0.50 
Brain natriuretic 
peptide (pg/L) 
522 (239-
1142) 
71 (35-256) - - <0.001 
Left ventricular 
ejection fraction (%) 
29±9† 29±10† 58±7 - <0.001 
Creatinine (µmol/L) 127±37*†‡ 103±24† 87±20 76±15 <0.001 
Estimated glomerular 
filtration rate 
(ml/min/1.73m2)
 
50±17*†‡ 62±16‡ 72±15 84±9 <0.001 
Hypertension 27 (55%)‡ 17 (46%) 27 (63%) 6 (16%) 0.006 
Diabetes mellitus 18 (37%)‡ 8 (22%)‡ 8 (19%)‡ 0 0.003 
Chronic obstructive 
pulmonary disease 
7 (14%)‡ 2 (5%) 3 (7%) 0 0.14 
Smoker 25 (51%)‡ 20 (54%)‡ 14 (33%)‡ 2(5%) <0.001 
Haematological parameters 
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Haemoglobin (g/dL) 12.2±2.0*†‡ 13.8±1.6 13.4±1.7 14.0±1.0 <0.001 
Neutrophils (103 per 
µL) 
5.66±2.43*†‡ 4.10±1.18 3.70±1.16 3.58±1.06 <0.001 
Lymphocytes (103 per 
µL) 
1.33±0.69 1.70±0.71 1.63±0.55 1.77±0.60 0.058 
Monocytes (per µL) 856±301*†‡ 630±164 544±140 513±193 <0.001 
Combined free light 
chains (mg/L) 
62 (45-92)*†‡ 38 (27-44)‡ 25 (20-42) 24 (20-36) <0.001 
Cystatin C (mg/L) 2.08±0.66*†‡ 1.35±0.36‡ 1.21±0.51 0.99±0.17 <0.001 
High sensitivity C-
reactive protein (mg/L) 
12.6 (4.7-
29.7)*†‡ 
1.9 (1.1-4.8) 1.5 (0.8-3.5) 1.3 (0.7-3.3) <0.001 
Interleukin-6 (pg/mL) 11 (7-16)*†‡ 2.6 (1-4) 1.9 (1-3) 1.7 (0.5-3.0) <0.001 
Medications 
Aspirin 36 (73%)‡ 31 (84%)‡ 37 (86%)‡ 5 (14%) <0.001 
ACEI/ARA 39 (80%)‡ 31 (84%)‡ 33 (77%)‡ 4 (11%) <0.001 
Loop diuretics 48 (98%)*†‡ 31 (84%)†‡ 2 (5%)‡ 0 <0.001 
Statins 41 (84%)‡ 33 (89%)‡ 38 (88%)‡ 4 (11%) <0.001 
Beta-blockers 20 (41%)*†‡ 28 (76%)‡ 33 (77%)‡ 0 <0.001 
Data are presented as mean±SD for normally distributed variables and median (IQR) for non-
normally distributed variables. *p<0.05 vs. stable heart failure; †p<0.05 vs. stable coronary 
artery disease; ‡p<0.05 vs. healthy controls; ACEI, angiotensin converting enzyme inhibitor; 
ARA, angiotensin receptor antagonists.  
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Table 2. Longitudinal analysis of the study parameters. 
N=32 Admission Discharge Follow up p 
Combined free light 
chains (mg/L) 
61 (45-77) 62 (48-83) 63 (48-86) 0.14 
Cystatin C (mg/L) 1.90±0.49 1.95±0.53 2.04±0.56 0.072 
High sensitivity C-
reactive protein (mg/L) 
13.1 (5.0- 29.9) 9.4 (2.9-27.1) 6.9 (2.7-17.5) 0.42 
Brain natriuretic 
peptide (pg/L) 
480 (230-900)* 253 (183-581) 218 (74-342) 0.017 
Interleukin-6 (pg/mL) 12 (6–16) 8 (4–18) 6 (3–14) 0.60 
*p<0.05 vs. 3 months follow up. 
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Table 3. Cox regression analysis for predictors of the primary outcome 
(combination of death from any cause and cardiology related hospital 
admissions) and the secondary outcome (death from any cause alone). 
 Primary outcome Secondary outcome 
Hazard ratio 
[95.0% CI] 
p 
value 
Hazard ratio 
[95.0% CI] 
p value 
Univariate analysis 
Age 1.01 [0.97-1.06] 0.63 1.03 [0.98-1.09] 0.27 
Sex 1.09 [0.41-2.86] 0.87 1.25 [0.42-3.72] 0.69 
Previous myocardial infarction 1.13 [0.44-2.88] 0.80 1.16 [0.39-3.46] 0.79 
Hypertension 1.13 [0.45-2.81] 0.80 1.10 [0.38-3.18] 0.85 
Diabetes 0.95 [0.37-2.45] 0.92 0.62 [0.19-2.00] 0.42 
Smoking 1.96 [0.77-5.00] 0.16 2.90 [0.91-9.26] 0.07 
Systolic blood pressure 1.00 [0.97-1.02] 0.69 1.00 [0.97-1.03] 0.96 
Body mass index 0.84 [0.70-1.01] 0.06 0.79 [0.63-1.01] 0.06 
Brain natriuretic peptide 1.00 [1.00-1.00] 0.07 1.00 [1.00-1.00] 0.11 
Left ventricular ejection fraction 0.95 [0.91-1.00] 0.07 0.93 [0.87-0.99] 0.017 
Creatinine 1.01 [1.00-1.03] 0.07 1.02 [1.00-1.04] 0.026 
Estimated glomerular filtration 
rate 
0.98 [0.94-1.01] 0.20 0.96 [0.91-1.01] 0.09 
Haemoglobin 0.99 [0.75-1.30] 0.93 0.86 [0.60-1.26] 0.45 
Neutrophils 0.87 [0.65-1.16] 0.33 0.91 [0.67-1.25] 0.58 
Lymphocytes 0.99 [0.37-2.67] 0.99 0.70 [0.23-2.15] 0.53 
Monocytes 1.00 [0.99-1.00] 0.09 1.00 [0.99-1.00] 0.45 
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Combined free light chains 1.02 [1.01-1.03] 0.0001 1.02 [1.01-1.04] <0.001 
Cystatin C 1.47 [0.80-2.69] 0.22 1.82 [0.93-3.56] 0.08 
C-reactive protein 1.00 [0.98-1.01] 0.75 1.00 [0.99-1.02] 0.97 
Interleukin-6 0.99 [0.96-1.02] 0.50 0.99 [0.96-1.03] 0.58 
Multivariate analysis 
Combined free light chains* 1.08 [1.04-1.13] <0.00
1 
1.10 [1.03-1.18] 0.003 
Combined free light chains** 1.10 [1.04-1.16] 0.001 1.16 [1.03-1.30] 0.011 
*Adjusted of age, gender, brain natriuretic peptide and cystatin C levels; **Adjusted 
of age, gender, brain natriuretic peptide, cystatin C levels and ejection fraction. CI, 
confidence interval 
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